Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

A Novel MOA-based Bioluminescent Bioassay for Quantitative Measurement of Anti-VEGF Antibody Potency and Stability

Part # PS336


Jennifer Wilkinson, Matt Robers, Frank Fan and Mei Cong
Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711

We developed a bioluminescent reporter-based bioassay that measures VEGF stimulation/inhibition of KDR (VEGFR2). This assay overcomes many of the limitations of the current endothelial cell proliferation assays, and can be used for the discovery and development of novel biologic therapies aimed at either inducing or inhibiting the VEGF response. The bioassay utilizes cryopreserved thaw-and use cells, eliminating the need for cell culture. This assay format offer the benefits of convenience, reproducibility, and transferability. The assay cab be performed in less than 7 hours, which is a significant improvement over a 4-5 day traditional cell proliferation assay. Finally, using the anti-VEGF antibody drug bevacizumab, we demonstrate that the assay is suitable for potency and stability studies per ICH guidelines.

Printed in USA.